Blue Ash Therapeutics, Forest Laboratories deal

Blue Ash granted Forest exclusive, worldwide rights to antiarrhythmic candidate azimilide. Last year, Blue Ash licensed the potassium channel blocker from Warner Chilcott plc (NASDAQ:WCRX, Dublin, ...